Table 1.

Select ongoing trials evaluating genomic biomarkers to guide management within prostate cancer.

Trial Name	Full/formal name of trial	Common name	Setting	Phase	Number of participants	Status (March 2022)
NRG GU009 NCT04513717	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score	PREDICT-RT	Upfront localized	III	2478	Recruiting
NRG GU010 NCT05050084	Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score	GUIDANCE	Upfront localized	III	2050	Recruiting
NCT04396808	Genomics in Michigan to AdJust Outcomes in Prostate CanceR or Men With Newly Diagnosed Favorable Risk Prostate Cancer	G-MAJOR	Upfront localized	III	350	Recruiting
NRG GU006 NCT03371719	Biomarker Trial of Apalutamide and Radiation for Recurrent Prostate cancer	BALANCE	Recurrent	II	311	Active, not recruiting
EA8183 NCT04484818	Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer	ERADICATE	Post-prostatectomy	III	810	Recruiting
NCT02783950	Genomics in Michigan Impacting Observation or Radiation	G-MINOR	Post-prostatectomy	N/A	356	Active, not recruiting